← Back to screener

Opus Genetics, Inc. IRD

Rank #2376 · Nasdaq · $0.3B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
21.5
P/E
-5.2
P/B
5.99
ROE
-115.3%
Op. Margin
-564.7%
Debt Ratio
23%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -5.2x, P/B 5.99x. Ranks in the top 80% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -115.3%. Ranks in the top 95% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 23%. Ranks in the top 14% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 42.3% year over year. Ranks in the top 97% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B$-0.0B$-0.0B$0.0B–56
2012–$-0.0B$-0.0B$0.0B–77
2013$0.0B$-0.0B$-0.0B$0.0B–138
2014–$-0.0B$-0.0B$0.0B–73
2015–$-0.0B$-0.0B$0.0B–73
2016–$-0.0B$-0.0B$0.0B–48
2017–$-0.0B$-0.0B$0.0B–15
2018–$-0.0B$-0.0B$0.0B–68
2019$0.0B$-0.0B$-0.0B$0.0B-684.633
2020–$-0.0B$-0.0B$-0.0B–-550
2021$0.0B$-0.0B$-0.0B$-0.0B–-412
2022$0.0B$-0.0B$-0.1B$-0.0B-3854.8-29
2023$0.0B$0.0B$0.0B$0.0B45.712
2024$0.0B$-0.0B$-0.0B$0.0B-55.59
2025$0.0B$-0.1B$-0.1B$0.0B-564.723

← See the full screener